323 [18F]FDG-PET/CT to prevent futile surgery: a blinded, randomised controlled multicentre trial 4 Table 11. Incidental [18F]FDG-PET/CT findings (whole-group analysis) n = 132 incidental [18F]FDG-avid findings on [18F]FDG-PET with diagnostic and/or therapeutic consequence 20 (15%) Thyroid incidentaloma 19 (14%) ipsilateral 6 (5%) contralateral 12 (9%) bilateral 1 (1%) FNAC* 13 (10%) Bethesda I 2 (2%) Bethesda II 6 (5%) Bethesda III 3 (2%) Bethesda IV 2 (2%) Histopathology 11 (8%) Benign 9 (7%) unbeneficial extension of planned diagnostic surgery with isthmus nodulectomy 2 (25) unbeneficial extension of planned diagnostic surgery to total thyroidectomy 4 (3%)* Malignant 2 (2%) extension of planned diagnostic surgery to total thyroidectomy 0 (0%)** Ultrasound follow-up unchanged 2 (2%) Cervical lymph node 9 mm, reactive on FNAC 1 (1%) Axillary lymph nodes <10 mm, reactive on FNAC 1 (1%) without diagnostic and/or therapeutic consequence Thyroiditis 9 (7%) Cervical lymph nodes <6 mm, reactive based on history of sinusitis/pharyngitis 8 (6%) Occipital lymph nodes 5 mm, reactive based on medical history 1 (1%) Axillary lymph nodes <5 mm, reactive based on medical history 1 (1%) Supraclavicular lymph nodes, non-enlarged, reactive based on medical history 1 (1%) Paratracheal lymph nodes, non-enlarged, reactive based on history of respiratory tract infection 1 (1%) Posttraumatic focal uptake in rib 1 (1%) Posttraumatic uptake in humerus 1 (1%) Synovitis in sternoclavicular joint 1 (1%) Accessory parotid tissue 1 (1%) incidental findings on (low-dose) CT with diagnostic and/or therapeutic consequence Lung nodule 4.5 mm, CT evaluation nonspecific, most likely benign 1 (1%) without diagnostic and/or therapeutic consequence Lung nodule <5mm in low-risk patient 3 (2%) Skeletal cyst dd intraosseous ganglion 1 (1%) Other incidental findings upon conduction of [18F]FDG-PET/CT Increased serum glucose, possible diabetes mellitus 1 (1%) Total incidental findings 41 (31%) Total no. of patients with findings with diagnostic and/or therapeutic consequences 22 (17%) Justified diagnostic and/or therapeutic consequences for disease 3 (2%) Unbeneficial major consequences*** 4 (3%) Unbeneficial minor consequences**** 15 (11%)
RkJQdWJsaXNoZXIy MTk4NDMw